Cynata Therapeutics Ltd has released a press release.
Phase 3 Osteoarthritis Clinical Trial Commences
Filed with ASX ·
6ix hasn’t read this filing yet.
Cynata Therapeutics Limited on 6ix
Earlier from Cynata Therapeutics
- Potential Utility of Cymerus MSCs in Heart Attack Model
- Cymerus MSCs Demonstrate Efficacy in Preclinical Lung Disease Study
- Cymerus MSCs Effective in Preclinical Lung Disease Study
- Patient Enrolment Opens in COVID-19 Clinical Trial
- Cynata Appoints Dr Geoff Brooke as Chairman
Later from Cynata Therapeutics
- CYP Closes $15m Institutional Placement to Expand Pipeline
- Investor Presentation
- Cynata Therapeutics Secures $15m Placement Led By $10m from Healthcare Investor BioScience Managers to Expand Development Pipeline
- Offer Booklet and Entitlement & Acceptance Form
- Completion of Entitlement Offer and Shortfall Placement
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics